Big Pharma went all in to kill drug pricing negotiations

For decades, the drug industry has yelled bloody murder each time Congress considered a regulatory measure that threatened its profits. But the hyperbole reached a new pitch in recent weeks as the Senate moved to adopt modest drug pricing negotiation measures in the Inflation Reduction Act.

Related Keywords

Boston ,Massachusetts ,United States ,Americans ,America ,American ,Aaron Kesselheim ,Henry Waxman ,Craig Garthwaite ,Andy Slavitt ,Thomas Copmann ,Newt Gingrich ,Michelle Mcmurry Heath ,David Mitchell ,Vincent Rajkumar ,Northwestern University Kellogg School Of Management ,American Heart Association ,Centers For Medicare Medicaid Services ,Merck Co ,American Diabetes Association ,Biotechnology Innovation Organization ,Pfizer ,Program On Regulation ,Association Of America ,Bristol Myers Squibb ,Congressional Budget Office ,Johnson ,American Cancer Society ,Inflation Reduction ,Pharmaceutical Research ,Medicaid Services ,Myers Squibb ,President Bill Clinton ,Proprietary Association ,House Speaker Newt Gingrich ,Affordable Care ,Northwestern University ,Kellogg School ,Mayo Clinic ,Affordable Drugs ,